{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:10:44Z","timestamp":1780564244812,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oral Maxillofac Surg"],"DOI":"10.1007\/s10006-024-01221-6","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T02:22:10Z","timestamp":1706754130000},"page":"849-857","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Survey of the association between tooth extraction and development of medication-related osteonecrosis of the jaw in patients undergoing cancer treatment with bone-modifying agents"],"prefix":"10.1007","volume":"28","author":[{"given":"Mai","family":"Nozawa-Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenobu","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Kanemaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Soga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moe","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanae","family":"Niimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadaharu","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"1221_CR1","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cort\u00e9s J (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372:724\u2013734","journal-title":"N Engl J Med"},{"key":"1221_CR2","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, de Angelis F, DomineM CP, HochmairMJ PSF, Cheng SYS, Bischoff HG, Peled N, Grossi F, Jennens RR, ReckM HR, Garon EB, BoyerM R-V, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, PietanzaMC GMC (2018) Pembrolizumab plus chemotherapy in metastatic non\u2013 small-cell lung cancer. N Engl J Med 378:2078\u20132092","journal-title":"N Engl J Med"},{"key":"1221_CR3","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1634\/theoncologist.2007-0245","volume":"15","author":"M Aapro","year":"2010","unstructured":"Aapro M, Saad F, Costa L (2010) Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases. Oncologist 15:1147\u20131158","journal-title":"Oncologist"},{"key":"1221_CR4","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1007\/s00520-019-04676-6","volume":"27","author":"A Mjelstad","year":"2019","unstructured":"Mjelstad A, Zakariasson G, Valachis A (2019) Optimizing antiresorptive treatment in patients with bone metastases: time to initiation, switching strategies, and treatment duration. Support Care Cancer 27:3859\u20133867","journal-title":"Support Care Cancer"},{"key":"1221_CR5","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","volume":"80","author":"SL Ruggiero","year":"2022","unstructured":"Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D (2022) American Association of Oral and Maxillofacial Surgeons\u2019 position paper on medication-related osteonecrosis of the Jaws-2022 update. J Oral Maxillofac Surg 80:920\u2013943. https:\/\/doi.org\/10.1016\/j.joms.2022.02.008","journal-title":"J Oral Maxillofac Surg"},{"key":"1221_CR6","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"F Saad","year":"2002","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458\u20131468. https:\/\/doi.org\/10.1093\/jnci\/94.19.1458","journal-title":"J Natl Cancer Inst"},{"key":"1221_CR7","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","volume":"23","author":"F Saad","year":"2012","unstructured":"Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT et al (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341\u20131347. https:\/\/doi.org\/10.1093\/annonc\/mdr435","journal-title":"Ann Oncol"},{"key":"1221_CR8","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","volume":"21","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2013the zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol 21:3150\u20133157. https:\/\/doi.org\/10.1200\/JCO.2003.04.105","journal-title":"J Clin Oncol"},{"key":"1221_CR9","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038.Protocol19","volume":"16","author":"GN Hortobagyi","year":"1998","unstructured":"Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C et al (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16:2038\u20132044. https:\/\/doi.org\/10.1200\/JCO.1998.16.6.2038.Protocol19","journal-title":"J Clin Oncol"},{"key":"1221_CR10","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1056\/NEJM199602223340802","volume":"334","author":"JR Berenson","year":"1996","unstructured":"Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S et al (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia study group. N Engl J Med 334:488\u2013493. https:\/\/doi.org\/10.1056\/NEJM199602223340802","journal-title":"N Engl J Med"},{"key":"1221_CR11","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","volume":"16","author":"JR Berenson","year":"1998","unstructured":"Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S et al (1998) Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia study group. J Clin Oncol 16:593\u2013602. https:\/\/doi.org\/10.1200\/JCO.1998.16.2.593","journal-title":"J Clin Oncol"},{"key":"1221_CR12","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","volume":"20","author":"JR Berenson","year":"2002","unstructured":"Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC et al (2002) American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 20:3719\u20133736. https:\/\/doi.org\/10.1200\/JCO.2002.06.037","journal-title":"J Clin Oncol"},{"key":"1221_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/13696998.2019.1651122","volume":"23","author":"A Stopeck","year":"2020","unstructured":"Stopeck A, Brufsky A, Kennedy L, Bhatta S, Bhowmik D, Buchanan J et al (2020) Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ 23:37\u201347. https:\/\/doi.org\/10.1080\/13696998.2019.1651122","journal-title":"J Med Econ"},{"key":"1221_CR14","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00774-019-01052-6","volume":"38","author":"HL Jeon","year":"2020","unstructured":"Jeon HL, Oh IS, Baek YH, Yang H, Park J, Hong S et al (2020) Zoledronic acid and skeletal-related events in patients with bone metastatic cancer or multiple myeloma. J Bone Miner Metab 38:254\u2013263. https:\/\/doi.org\/10.1007\/s00774-019-01052-6","journal-title":"J Bone Miner Metab"},{"key":"1221_CR15","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1182\/bloodadvances.2020002378","volume":"5","author":"E Terpos","year":"2021","unstructured":"Terpos E, Raje N, Croucher P, Garcia-Sanz R, Leleu X, Pasteiner W et al (2021) Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study. Blood Adv 5:725\u2013736. https:\/\/doi.org\/10.1182\/bloodadvances.2020002378","journal-title":"Blood Adv"},{"key":"1221_CR16","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Dami\u00e3o R, Brown J, Karsh L et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813\u2013822. https:\/\/doi.org\/10.1016\/S0140-6736(10)62344-6","journal-title":"Lancet"},{"key":"1221_CR17","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132\u20135139. https:\/\/doi.org\/10.1200\/JCO.2010.29.7101","journal-title":"J Clin Oncol"},{"key":"1221_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00774-016-0810-7","volume":"35","author":"T Yoneda","year":"2017","unstructured":"Japanese Allied Committee on Osteonecrosis of the Jaw, Yoneda T, Hagino H et al (2017) Antiresorptive agent-related osteonecrosis of the jaw: position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab 35:6\u201319","journal-title":"J Bone Miner Metab"},{"key":"1221_CR19","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1200\/JCO.19.01186","volume":"37","author":"N Yarom","year":"2019","unstructured":"Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL et al (2019) Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline. J Clin Oncol 37:2270\u20132290. https:\/\/doi.org\/10.1200\/JCO.19.01186","journal-title":"J Clin Oncol"},{"key":"1221_CR20","unstructured":"Japanese Allied Committee on Osteonecrosis of the Jaw, Kishimoto H, Hagino H, et al. (2023) Antiresorptive agent-related osteonecrosis of the jaw: position Paper 2023 of the Japanese Allied Committee on Osteonecrosis of the Jaw (in Japanese). Japanese Society of Oral and Maxillofacial Surgeons, https:\/\/www.jsoms.or.jp\/medical\/pdf\/work\/guideline_202307.pdf, 17 Aug 2023."},{"key":"1221_CR21","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/s0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115\u20131117. https:\/\/doi.org\/10.1016\/s0278-2391(03)00720-1","journal-title":"J Oral Maxillofac Surg"},{"key":"1221_CR22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0022034510397196","volume":"90","author":"A Barasch","year":"2011","unstructured":"Barasch A, Cunha-Cruz J, Curro FA, Hujoel P, Sung AH, Vena D et al (2011) Risk factors for osteonecrosis of the jaws: a case-control study from the Condor Dental PBRN. J Dent Res 90:439\u2013444. https:\/\/doi.org\/10.1177\/0022034510397196","journal-title":"J Dent Res"},{"key":"1221_CR23","doi-asserted-by":"publisher","first-page":"4634","DOI":"10.1200\/JCO.2008.16.2768","volume":"26(28)","author":"A Kyrgidis","year":"2008","unstructured":"Kyrgidis A, Vahtsevanos K, Koloutsos G, Andreadis C, Boukovinas I, Teleioudis Z et al (2008) Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J Clin Oncol 26:4634\u20134638. https:\/\/doi.org\/10.1200\/JCO.2008.16.2768","journal-title":"J Clin Oncol"},{"key":"1221_CR24","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jcms.2015.03.039","volume":"43","author":"S Otto","year":"2015","unstructured":"Otto S, Tr\u00f6ltzsch M, Jambrovic V, Panya S, Probst F, Ristow O et al (2015) Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development? J Craniomaxillofac Surg 43:847\u2013854. https:\/\/doi.org\/10.1016\/j.jcms.2015.03.039","journal-title":"J Craniomaxillofac Surg"},{"key":"1221_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201343","volume":"13","author":"S Soutome","year":"2018","unstructured":"Soutome S, Hayashida S, Funahara M, Sakamoto Y, Kojima Y, Yanamoto S et al (2018) (2018) Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: is tooth extraction a risk factor? PLoS ONE 13:e0201343. https:\/\/doi.org\/10.1371\/journal.pone.0201343","journal-title":"PLoS ONE"},{"key":"1221_CR26","doi-asserted-by":"publisher","first-page":"17226","DOI":"10.1038\/s41598-021-96480-8","volume":"11","author":"S Soutome","year":"2021","unstructured":"Soutome S, Otsuru M, Hayashida S, Murata M, Yanamoto S, Sawada S et al (2021) Relationship between tooth extraction and development of medication-related osteonecrosis of the jaw in cancer patients. Sci Rep 11:17226. https:\/\/doi.org\/10.1038\/s41598-021-96480-8","journal-title":"Sci Rep"},{"key":"1221_CR27","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.ijom.2012.06.020","volume":"41","author":"T Yamazaki","year":"2012","unstructured":"Yamazaki T, Yamori M, Ishizaki T, Asai K, Goto K, Takahashi K et al (2012) Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int J Oral Maxillofac Surg 41:1397\u20131403. https:\/\/doi.org\/10.1016\/j.ijom.2012.06.020","journal-title":"Int J Oral Maxillofac Surg"},{"key":"1221_CR28","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.oraloncology.2012.03.009","volume":"48","author":"M Mozzati","year":"2012","unstructured":"Mozzati M, Arata V, Gallesio G (2012) Tooth extraction in patients on zoledronic acid therapy. Oral Oncol 48:817\u2013821. https:\/\/doi.org\/10.1016\/j.oraloncology.2012.03.009","journal-title":"Oral Oncol"},{"key":"1221_CR29","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.joms.2013.01.006","volume":"71","author":"M Scoletta","year":"2013","unstructured":"Scoletta M, Arata V, Arduino PG, Lerda E, Chiecchio A, Gallesio G et al (2013) Tooth extractions in intravenous bisphosphonate-treated patients: a refined protocol. J Oral Maxillofac Surg 71:994\u2013999. https:\/\/doi.org\/10.1016\/j.joms.2013.01.006","journal-title":"J Oral Maxillofac Surg"},{"key":"1221_CR30","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.jcms.2016.07.026","volume":"44","author":"T Mucke","year":"2016","unstructured":"Mucke T, Deppe H et al (2016) Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid \u2013 a prospective study over 6 years. J Craniomaxillofac Surg 44:1689\u20131693. https:\/\/doi.org\/10.1016\/j.jcms.2016.07.026","journal-title":"J Craniomaxillofac Surg"},{"key":"1221_CR31","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1007\/s00198-017-4063-7","volume":"28","author":"T Hasegawa","year":"2017","unstructured":"Hasegawa T, Kawakita A, Japanese Study Group of Cooperative Dentistry with Medicine (2017) A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ\u202f? Osteoporos Int 28:2465\u20132473. https:\/\/doi.org\/10.1007\/s00198-017-4063-7","journal-title":"Osteoporos Int"}],"container-title":["Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10006-024-01221-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10006-024-01221-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10006-024-01221-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T03:14:39Z","timestamp":1717384479000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10006-024-01221-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["1221"],"URL":"https:\/\/doi.org\/10.1007\/s10006-024-01221-6","relation":{},"ISSN":["1865-1569"],"issn-type":[{"value":"1865-1569","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]},"assertion":[{"value":"28 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Niigata University (approval no. 2020\u20130443). Since this is a retrospective study using patients\u2019 medical records, examination results, etc., we believe that Informed consent is not necessary. However, since the subject\u2019s will should be respected when participating in the study, consideration was given to the subject by not only disclosing the information on the university\u2019s website \u201cNotice of Clinical Research\u201d but also by posting a notice about the study in the clinic room to disclose information about the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}